Sichuan Haoyun Industrial Co., Ltd.

Main study purpose: According to the regulations on bioequivalence test, Acipimox Capsules (trade name: OLBETAM, specification: 0.25g) of which Pfizer Limited is the licensee was selected as the reference preparation. The human bioequivalence test of the test preparation Acipimox Capsules (specification: 0.25g) produced and provided by Sichuan Haoyun Pharmaceutical Co., Ltd. was conducted under fasting and postprandial administration conditions, and the pharmacokinetic characteristics of the test preparation and the reference preparation were compared to evaluate the bioequivalence of the two preparations under fasting or postprandial administration conditions. Secondary study purpose: Observe the safety of oral administration of the test preparation Acipimox Capsules (specification: 0.25g) and the reference preparation Acipimox Capsules (trade name: OLBETAM, specification: 0.25g) to healthy subjects.